open access

Ahead of Print
Research paper
Published online: 2021-04-28
Get Citation

Triple negative phenomenon in endometrial cancer: recognition criteria and impact on survival

Michal Bulsa1, Elzbieta Urasinska1
DOI: 10.5603/GP.a2021.0082
·
Pubmed: 33914326
Affiliations
  1. Department of Pathology, Pomeranian Medical University, Szczecin, Poland

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2021-04-28

Abstract

Objectives: Endometrial cancer is the most common malignant cancer of female reproductive organs. The number of diagnosed cases of endometrial cancer is increasing from year to year. Endometrial cancer is a neoplasm with a good survival rate. However, there are also cases with a fast, aggressive course. In recent years, the triple negative phenomenon (TNP) has been identified as one of the factors determining shorter survival in patients with endometrial cancer.

Material and methods: The study covered 265 patients with histopathologically confirmed endometrial cancer. Patients were divided into two groups: 1) patients with endometrial cancer with TNP; 2) patients with endometrial cancer without TNP.

Tissue microarrays (TMA) were examined with immunohistochemistry to evaluate the expression of estrogen, progesterone and HER2 receptors. In several cases FISH method was used to assess HER2. The expression was evaluated by computer image analysis using the Nuclear Image Analysis virtual microscopy system. The evaluation of HER2 expression was performed manually. The criterion for TNC diagnosis was H-Score < 50 or < 75 and Allred score < 4.

Results: Depending on the scoring system used, TNP was found in from 10.19% to 15.09% of cases. Regardless of the criteria employed in endometrial cancer, the presence of TNP was neither a factor increasing the risk of death nor it affected the patients' survival.

Conclusions: The proportion of TNP diagnosed in endometrial cancer depends on the examined population and the diagnostic criteria. The incidence of TNP did not affect the survival of patients.

Abstract

Objectives: Endometrial cancer is the most common malignant cancer of female reproductive organs. The number of diagnosed cases of endometrial cancer is increasing from year to year. Endometrial cancer is a neoplasm with a good survival rate. However, there are also cases with a fast, aggressive course. In recent years, the triple negative phenomenon (TNP) has been identified as one of the factors determining shorter survival in patients with endometrial cancer.

Material and methods: The study covered 265 patients with histopathologically confirmed endometrial cancer. Patients were divided into two groups: 1) patients with endometrial cancer with TNP; 2) patients with endometrial cancer without TNP.

Tissue microarrays (TMA) were examined with immunohistochemistry to evaluate the expression of estrogen, progesterone and HER2 receptors. In several cases FISH method was used to assess HER2. The expression was evaluated by computer image analysis using the Nuclear Image Analysis virtual microscopy system. The evaluation of HER2 expression was performed manually. The criterion for TNC diagnosis was H-Score < 50 or < 75 and Allred score < 4.

Results: Depending on the scoring system used, TNP was found in from 10.19% to 15.09% of cases. Regardless of the criteria employed in endometrial cancer, the presence of TNP was neither a factor increasing the risk of death nor it affected the patients' survival.

Conclusions: The proportion of TNP diagnosed in endometrial cancer depends on the examined population and the diagnostic criteria. The incidence of TNP did not affect the survival of patients.

Get Citation

Keywords

endometrial cancer; triple negative endometrial cancer; triple negative cancer; H-Score; Allred Score; triple negative phenomenon

About this article
Title

Triple negative phenomenon in endometrial cancer: recognition criteria and impact on survival

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-04-28

DOI

10.5603/GP.a2021.0082

Pubmed

33914326

Keywords

endometrial cancer
triple negative endometrial cancer
triple negative cancer
H-Score
Allred Score
triple negative phenomenon

Authors

Michal Bulsa
Elzbieta Urasinska

References (34)
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.
  3. Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014; 6: 429–435.
  4. Zhang GY, Wu LY, Li B, et al. Retrospective analysis of prognostic variables and clinical outcomes in surgically staged intermediate risk endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013; 169(2): 309–316.
  5. Trovik J, Wik E, Werner HMJ, et al. MoMaTEC study group. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer. 2013; 49(16): 3431–3441.
  6. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004; 95(1): 133–138.
  7. Wik E, Ræder MB, Krakstad C, et al. Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 2013; 19(5): 1094–1105.
  8. Backes FJ, Walker CJ, Goodfellow PJ, et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol. 2016; 141(2): 312–317.
  9. Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011; 8(5): 261–271.
  10. Lapińska-Szumczyk S, Supernat A, Majewska H, et al. HER2-positive endometrial cancer subtype carries poor prognosis. Clin Transl Sci. 2014; 7(6): 482–488.
  11. Kalogiannidis I, Petousis S, Bobos M, et al. HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. Arch Gynecol Obstet. 2014; 290(6): 1231–1237.
  12. Zhang Y, Zhao D, Gong C, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol. 2015; 13: 208.
  13. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016; 293(2): 247–269.
  14. Kothari R, Morrison C, Richardson D, et al. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol. 2010; 118(2): 172–175.
  15. Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer. 2011; 104(10): 1611–1618.
  16. Jiang XF, Tang Ql, Shen XM, et al. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma. Pathol Res Pract. 2012; 208(12): 730–735.
  17. Altundag O, Dursun P, Roach EC, et al. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy. J BUON. 2013; 18(1): 289.
  18. Porzio R, Cordini C, Rodolfi AM, et al. Triple negative endometrial cancer: Incidence and prognosis in a monoinstitutional series of 220 patients. Oncol Lett. 2020; 19(3): 2522–2526.
  19. Bulsa M, Urasińska E. Triple negative endometrial cancer. Ginekol Pol. 2017; 88(4): 212–214.
  20. Graham AD, Faratian D, Rae F, et al. Tissue microarray technology in thee routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2008; 52(7): 847–855.
  21. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 2008; 18(2): 89–97.
  22. McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985; 109(8): 716–721.
  23. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2007; 106(2): 325–333.
  24. Thike AA, Chng MJ, Fook-Chong S, et al. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology. 2001; 33(1): 21–25.
  25. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11(2): 155–168.
  26. Gottwald L, Kubiak R, Pasz-Walczak G, et al. The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer. Ginekol Pol. 2013; 84(2): 95–101.
  27. Wolff AC, Hammond ME, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline focused update. J Clin Oncol. 2018; 36(20): 2105–2122.
  28. Ryś-Bednarska M, Romanowicz H. Potrójnie ujemny rak piersi — diagnostyka i leczenie. Nowotwory Journal of Oncology. 2012; 62(6): 450–454.
  29. Gonçalves H, Guerra MR, Duarte Cintra JR, et al. Survival study of triple-negative and non-triple-negative breast cancer in a Brazilian cohort. Clin Med Insights Oncol. 2018; 12: 1179554918790563.
  30. Liu N, Wang X, Sheng X. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis. Curr Opin Obstet Gynecol. 2011; 23(1): 19–23.
  31. Jagielski L, Jelen M, Kobierzycki C, et al. Increase of nuclear expression of metallothionein I/II in neoplastic transformation of the endomnetrium. Ginekol Pol. 2015; 86(3): 182–187.
  32. El-Sharkawy SL, Abbas NF, El-Henawy AMY, et al. Morphometric and DNA image analysis of endometrial hyperplasia and carcinoma. Appl Immunohistochem Mol Morphol. 2017; 25(1): 32–38.
  33. Miller J, Geisler JP, Manahan KJ, et al. Nuclear size, shape, and density in endometrial carcinoma: relationship to survival at over 5 years of follow-up. Does analyzing only cells occupying the G0-G1 peak add useful information? Int J Gynecol Cancer. 2004; 14(1): 138–144.
  34. Paulik R, Micsik T, Kiszler G, et al. An optimized image analysis algorithm for detecting nuclear signals in digital whole slides for histopathology. Cytometry A. 2017; 91(6): 595–608.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl